Innovative Diagnostic Capability Braingaze's patented eye movement technology, cognitive vergence, offers unique diagnostic and therapeutic solutions for cognitive disorders like ADHD and Alzheimer's, creating opportunities for partnerships with clinics and healthcare providers seeking advanced diagnostic tools.

Growing Clinical Adoption With solutions already used in leading clinics and recent collaborations such as the Tris Pharma partnership, there is potential to expand into additional healthcare facilities looking to adopt cutting-edge, evidence-based digital health solutions.

Funding and Accelerator Support Participation in programs like PepsiCo's Greenhouse Accelerator and recent funding rounds highlight a strong backing for product development and market expansion, making them a promising prospect for investors and corporate partners aiming to leverage health tech innovations.

Expansion of Digital Therapeutics Braingaze's launch of ADHD therapy apps across multiple platforms opens up opportunities to collaborate with educational institutions, telehealth providers, and patient advocacy groups seeking accessible cognitive health interventions.

Potential for Market Penetration With a modest revenue pipeline and international interdisciplinary team, Braingaze is positioned to scale its digital health solutions, appealing to large healthcare organizations and pharmaceutical companies interested in integrating innovative diagnostic and therapeutic technologies.